jueves, 4 de junio de 2020

Gilead’s remdesivir shows some benefit in patients with moderate Covid-19

Gilead’s remdesivir shows some benefit in patients with moderate Covid-19

Go West

Gilead’s remdesivir shows some benefit in patients with moderate Covid-19, new data show

By MATTHEW HERPER


GILEAD SCIENCES VIA AP
The drug helped patients with “moderate” disease recover faster when they received it for five days; the benefit when given for 10 days was unclear.

Despite economic crisis, prominent health tech startups draw big funding

Despite economic crisis, prominent health tech startups draw big funding

Go West

STAT Plus: Despite economic downturn, big names in health tech are drawing in significant funding

By ERIN BRODWIN


ADOBE
Just this month, three well-established health tech companies — Insitro, Mindstrong, and Amwell — raised more than $100 million each.

U.S. coronavirus transmission began in January, CDC analysis suggests

U.S. coronavirus transmission began in January, CDC analysis suggests

Go West

When did the coronavirus start spreading in the U.S.? Likely in January, CDC analysis suggests

By HELEN BRANSWELL


NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES/NIH
How early did local transmission of the SARS-CoV-2 virus begin in the United States? For the second time this week, scientists have proposed a new estimate.

New research offers hope for a way through the blood-brain barrier

New research offers hope for a way through the blood-brain barrier

Go West

STAT Plus: New research offers hope for a way through the blood-brain barrier, ‘the final frontier for drug delivery’

By MEGHANA KESHAVAN


ALEX HOGAN/STAT
A duo of preclinical studies recently demonstrated a new way to ferry medicines past the blood-brain barrier. And other research is on the way.

Allogene's off-the-shelf CAR-T cells produce responses in patients

Allogene's off-the-shelf CAR-T cells produce responses in patients

Go West

STAT Plus: Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows

By ADAM FEUERSTEIN


WELLCOME COLLECTION
The company released updated results from the first study of its off-the-shelf CAR-T cell therapy for an aggressive form of B-cell lymphoma.

San Francisco testing blitz shows Covid-19 hit mostly low-wage workers

San Francisco testing blitz shows Covid-19 hit mostly low-wage workers

Go West



When hard data are ‘heartbreaking’: Testing blitz in San Francisco shows Covid-19 struck mostly low-wage workers

By USHA LEE MCFARLING


COURTESY BARBARA RIES
The testing project is proving to be a national model, because of the challenges the organizers overcame and what it showed about the spread of Covid-19.

NIH: National Institute of Allergy and Infectious Diseases | Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases

NIH: National Institute of Allergy and Infectious Diseases | Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases

NIH/NIAID Template Banner



June 3, 2020 NIAID Funding News

Feature Articles 

Writing a Winning Application—Conduct a Self-Assessment

When applying for an independent research grant, you need demonstrable expertise in a scientific field because you need reviewers to deem you able to complete the work you propose.

Opportunities and Resources

NIAID seeks to evaluate and enhance the ability of U.S. and non-U.S. laboratories to participate in NIAID-funded and collaborative clinical studies through a recent request for proposals.

In The News

If challenges precipitated by the COVID-19 pandemic prevent you from applying on time, you may submit late, though no more than two weeks late, with the delay explained in your application’s cover letter. NIH will consider accepting late applications on a case-by-case basis.
See data on NIH-wide research investments, grant funding, and success rates for fiscal year 2019 and check out resources that allow you to further explore funding data.
We’ve updated our fiscal year paylines for National Research Service Award fellowship (F30, F31, F32) and training (T32, T35) grants. We now have fiscal year paylines for all grant types for which we use paylines.

Advice Corner

Federal Funding Accountability and Transparency Act reports do not go to NIH like so many others, so it's easy for grantees to overlook required reporting on first-tier subawards and executive compensation.

Reader Questions

New Funding Opportunities

  • RFA-HL-21-003, Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3, Clinical Trial Required).
  • PA-20-222, Research Supplements To Promote Diversity in Health-Related Research (Admin Supp, Clinical Trial Not Allowed)
Find other announcements at NIAID Opportunities & Announcements.
Send suggestions or comments to deaweb@niaid.nih.gov.